AU2005283085B2 - Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines - Google Patents
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines Download PDFInfo
- Publication number
- AU2005283085B2 AU2005283085B2 AU2005283085A AU2005283085A AU2005283085B2 AU 2005283085 B2 AU2005283085 B2 AU 2005283085B2 AU 2005283085 A AU2005283085 A AU 2005283085A AU 2005283085 A AU2005283085 A AU 2005283085A AU 2005283085 B2 AU2005283085 B2 AU 2005283085B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- alkyl
- alkylene
- compound
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- VFTLXHXYGQSOEN-UHFFFAOYSA-N 1h-imidazo[4,5-b][1,8]naphthyridine Chemical class C1=CN=C2NC3=NC=NC3=CC2=C1 VFTLXHXYGQSOEN-UHFFFAOYSA-N 0.000 title abstract description 3
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 title description 2
- 150000005232 imidazopyridines Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 200
- 238000000034 method Methods 0.000 claims abstract description 82
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 33
- 201000010099 disease Diseases 0.000 claims abstract description 31
- 241001465754 Metazoa Species 0.000 claims abstract description 29
- 102000004127 Cytokines Human genes 0.000 claims abstract description 22
- 108090000695 Cytokines Proteins 0.000 claims abstract description 22
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 22
- 230000003612 virological effect Effects 0.000 claims abstract description 15
- 230000001613 neoplastic effect Effects 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 230000001939 inductive effect Effects 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 186
- -1 nitro, hydroxy, mercapto Chemical group 0.000 claims description 116
- 229910052739 hydrogen Inorganic materials 0.000 claims description 110
- 239000001257 hydrogen Substances 0.000 claims description 110
- 125000002947 alkylene group Chemical group 0.000 claims description 95
- 150000003839 salts Chemical class 0.000 claims description 92
- 150000002431 hydrogen Chemical group 0.000 claims description 74
- 125000003118 aryl group Chemical group 0.000 claims description 73
- 125000001072 heteroaryl group Chemical group 0.000 claims description 65
- 125000000623 heterocyclic group Chemical group 0.000 claims description 61
- 125000003342 alkenyl group Chemical group 0.000 claims description 60
- 125000003545 alkoxy group Chemical group 0.000 claims description 55
- 229910052736 halogen Inorganic materials 0.000 claims description 49
- 150000002367 halogens Chemical class 0.000 claims description 49
- 125000005466 alkylenyl group Chemical group 0.000 claims description 46
- 125000000304 alkynyl group Chemical group 0.000 claims description 41
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 36
- 229920006395 saturated elastomer Polymers 0.000 claims description 32
- 125000000732 arylene group Chemical group 0.000 claims description 26
- 125000004450 alkenylene group Chemical group 0.000 claims description 25
- 125000004419 alkynylene group Chemical group 0.000 claims description 25
- 125000001188 haloalkyl group Chemical group 0.000 claims description 25
- 125000005549 heteroarylene group Chemical group 0.000 claims description 25
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 125000005842 heteroatom Chemical group 0.000 claims description 20
- 125000004414 alkyl thio group Chemical group 0.000 claims description 18
- 125000003282 alkyl amino group Chemical group 0.000 claims description 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 13
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 12
- 125000005529 alkyleneoxy group Chemical group 0.000 claims description 12
- 125000005532 aryl alkyleneoxy group Chemical group 0.000 claims description 12
- 125000004104 aryloxy group Chemical group 0.000 claims description 12
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 12
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 10
- 125000004043 oxo group Chemical group O=* 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 150000008575 L-amino acids Chemical class 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 12
- 229940111121 antirheumatic drug quinolines Drugs 0.000 abstract description 3
- 150000003248 quinolines Chemical class 0.000 abstract description 3
- 150000003530 tetrahydroquinolines Chemical class 0.000 abstract description 3
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 abstract description 2
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 abstract description 2
- 229940124669 imidazoquinoline Drugs 0.000 abstract description 2
- 239000002955 immunomodulating agent Substances 0.000 abstract description 2
- 229940121354 immunomodulator Drugs 0.000 abstract description 2
- 150000003222 pyridines Chemical class 0.000 abstract description 2
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical class C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 440
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 264
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 246
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 219
- 239000007787 solid Substances 0.000 description 200
- 238000006243 chemical reaction Methods 0.000 description 199
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 184
- 239000000243 solution Substances 0.000 description 181
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 175
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 171
- 239000000203 mixture Substances 0.000 description 140
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 111
- 239000011541 reaction mixture Substances 0.000 description 109
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 107
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 102
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 87
- 239000000463 material Substances 0.000 description 87
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 71
- 239000000047 product Substances 0.000 description 71
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 68
- 239000003921 oil Substances 0.000 description 68
- 235000019198 oils Nutrition 0.000 description 68
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 63
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 59
- 239000012043 crude product Substances 0.000 description 58
- 238000001914 filtration Methods 0.000 description 54
- 239000010410 layer Substances 0.000 description 52
- 239000002904 solvent Substances 0.000 description 52
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 50
- 239000012044 organic layer Substances 0.000 description 47
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 46
- 239000000706 filtrate Substances 0.000 description 42
- 150000001412 amines Chemical class 0.000 description 40
- 239000012267 brine Substances 0.000 description 40
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 40
- 238000007796 conventional method Methods 0.000 description 38
- 239000000741 silica gel Substances 0.000 description 34
- 229910002027 silica gel Inorganic materials 0.000 description 34
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 32
- 238000010992 reflux Methods 0.000 description 32
- 239000013078 crystal Substances 0.000 description 31
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 31
- 238000007429 general method Methods 0.000 description 31
- 239000011734 sodium Substances 0.000 description 31
- 235000017557 sodium bicarbonate Nutrition 0.000 description 29
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 29
- 238000003818 flash chromatography Methods 0.000 description 27
- 239000000843 powder Substances 0.000 description 27
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 26
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 26
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 26
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 25
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 24
- 239000003795 chemical substances by application Substances 0.000 description 24
- ZPMWWAIBJJFPPQ-UHFFFAOYSA-N 2-ethoxyacetyl chloride Chemical compound CCOCC(Cl)=O ZPMWWAIBJJFPPQ-UHFFFAOYSA-N 0.000 description 23
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 23
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 23
- 239000002244 precipitate Substances 0.000 description 21
- 239000000725 suspension Substances 0.000 description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 19
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 19
- ZRFUZDDJSQVQBY-UHFFFAOYSA-N 4-chloro-3-nitroquinoline Chemical compound C1=CC=CC2=C(Cl)C([N+](=O)[O-])=CN=C21 ZRFUZDDJSQVQBY-UHFFFAOYSA-N 0.000 description 18
- 239000006260 foam Substances 0.000 description 18
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 18
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 17
- 239000000908 ammonium hydroxide Substances 0.000 description 17
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 17
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 16
- 235000019341 magnesium sulphate Nutrition 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- JAFMOTJMRSZOJE-UHFFFAOYSA-N 1,1,1-trimethoxybutane Chemical compound CCCC(OC)(OC)OC JAFMOTJMRSZOJE-UHFFFAOYSA-N 0.000 description 14
- 239000012065 filter cake Substances 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 13
- 239000000651 prodrug Substances 0.000 description 13
- 229940002612 prodrug Drugs 0.000 description 13
- 239000007858 starting material Substances 0.000 description 13
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 238000005984 hydrogenation reaction Methods 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- 238000010189 synthetic method Methods 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 125000004122 cyclic group Chemical group 0.000 description 11
- 238000010828 elution Methods 0.000 description 11
- HDPNBNXLBDFELL-UHFFFAOYSA-N 1,1,1-trimethoxyethane Chemical compound COC(C)(OC)OC HDPNBNXLBDFELL-UHFFFAOYSA-N 0.000 description 10
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 10
- 150000003573 thiols Chemical class 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000005576 amination reaction Methods 0.000 description 9
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- QMRGVILFWQUZKR-UHFFFAOYSA-N 1-(aminomethyl)cyclobutan-1-ol Chemical compound NCC1(O)CCC1 QMRGVILFWQUZKR-UHFFFAOYSA-N 0.000 description 8
- XUSXTHMTOSFZII-UHFFFAOYSA-N 1-(aminomethyl)cyclohexan-1-ol Chemical compound NCC1(O)CCCCC1 XUSXTHMTOSFZII-UHFFFAOYSA-N 0.000 description 8
- ITIRVXDSMXFTPW-UHFFFAOYSA-N 1H-imidazo[4,5-c]quinoline Chemical group C1=CC=CC2=C(NC=N3)C3=CN=C21 ITIRVXDSMXFTPW-UHFFFAOYSA-N 0.000 description 8
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 8
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 8
- 150000002576 ketones Chemical class 0.000 description 8
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000003039 volatile agent Substances 0.000 description 8
- FGWYWKIOMUZSQF-UHFFFAOYSA-N 1,1,1-triethoxypropane Chemical compound CCOC(CC)(OCC)OCC FGWYWKIOMUZSQF-UHFFFAOYSA-N 0.000 description 7
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 7
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 7
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 7
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 101150043532 CISH gene Proteins 0.000 description 6
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 6
- 239000012346 acetyl chloride Substances 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 6
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 6
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000009904 heterogeneous catalytic hydrogenation reaction Methods 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 6
- RDOOEPVOAVLQCG-UHFFFAOYSA-N 1-[[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclohexan-1-amine Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CC1(N)CCCCC1 RDOOEPVOAVLQCG-UHFFFAOYSA-N 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- LBUWKUXIRPCSPJ-UHFFFAOYSA-N 4-[[(3-aminoquinolin-4-yl)amino]methyl]oxan-4-ol Chemical compound NC1=CN=C2C=CC=CC2=C1NCC1(O)CCOCC1 LBUWKUXIRPCSPJ-UHFFFAOYSA-N 0.000 description 5
- CJMLFTFOFQMDKG-UHFFFAOYSA-N 4-chloro-3-nitro-1,8-naphthyridine Chemical compound N1=CC=CC2=C(Cl)C([N+](=O)[O-])=CN=C21 CJMLFTFOFQMDKG-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 235000019502 Orange oil Nutrition 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000012452 mother liquor Substances 0.000 description 5
- 239000010502 orange oil Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- DXIAEURKHWGAFH-UHFFFAOYSA-N 1-(aminomethyl)cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NCC1(O)CCCCC1 DXIAEURKHWGAFH-UHFFFAOYSA-N 0.000 description 4
- FEALJKFIUQDJAV-UHFFFAOYSA-N 1-(aminomethyl)cyclopentan-1-ol Chemical compound NCC1(O)CCCC1 FEALJKFIUQDJAV-UHFFFAOYSA-N 0.000 description 4
- JYQMHTBJVMBKGR-UHFFFAOYSA-N 1-[[(3-amino-1,5-naphthyridin-4-yl)amino]methyl]cyclohexan-1-ol Chemical compound NC1=CN=C2C=CC=NC2=C1NCC1(O)CCCCC1 JYQMHTBJVMBKGR-UHFFFAOYSA-N 0.000 description 4
- XDXRYOOTWLBTPN-UHFFFAOYSA-N 1-[[(3-nitroquinolin-4-yl)amino]methyl]cyclohexan-1-ol Chemical compound [O-][N+](=O)C=1C=NC2=CC=CC=C2C=1NCC1(O)CCCCC1 XDXRYOOTWLBTPN-UHFFFAOYSA-N 0.000 description 4
- MDVQVSNLODTHDE-UHFFFAOYSA-N 1-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclopentan-1-ol Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCCC1 MDVQVSNLODTHDE-UHFFFAOYSA-N 0.000 description 4
- GRNOZCCBOFGDCL-UHFFFAOYSA-N 2,2,2-trichloroacetyl isocyanate Chemical compound ClC(Cl)(Cl)C(=O)N=C=O GRNOZCCBOFGDCL-UHFFFAOYSA-N 0.000 description 4
- RSFJVCHKGRUCIC-UHFFFAOYSA-N 2,4-dichloro-3-nitroquinoline Chemical compound C1=CC=CC2=C(Cl)C([N+](=O)[O-])=C(Cl)N=C21 RSFJVCHKGRUCIC-UHFFFAOYSA-N 0.000 description 4
- HQBUPOAKJGJGCD-UHFFFAOYSA-N 3h-imidazo[4,5-c]quinolin-4-amine Chemical class NC1=NC2=CC=CC=C2C2=C1N=CN2 HQBUPOAKJGJGCD-UHFFFAOYSA-N 0.000 description 4
- CGPIFQOTBHKPNM-UHFFFAOYSA-N 4-(aminomethyl)oxan-4-ol Chemical compound NCC1(O)CCOCC1 CGPIFQOTBHKPNM-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 150000001204 N-oxides Chemical class 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 4
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 4
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 4
- 150000001414 amino alcohols Chemical class 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 150000001805 chlorine compounds Chemical class 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000003840 hydrochlorides Chemical class 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 150000002513 isocyanates Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- UTOMICFLROGMAE-UHFFFAOYSA-N quinoline-3,4-diamine Chemical compound C1=CC=CC2=C(N)C(N)=CN=C21 UTOMICFLROGMAE-UHFFFAOYSA-N 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- KMDAVIGMFNJEHI-UHFFFAOYSA-N 1-[2-[(3-aminoquinolin-4-yl)amino]ethyl]cyclopropan-1-ol Chemical compound NC1=CN=C2C=CC=CC2=C1NCCC1(O)CC1 KMDAVIGMFNJEHI-UHFFFAOYSA-N 0.000 description 3
- LCMXJURFBWGAQJ-UHFFFAOYSA-N 1-[4-[[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]-4-hydroxypiperidin-1-yl]ethanone Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CC1(O)CCN(C(C)=O)CC1 LCMXJURFBWGAQJ-UHFFFAOYSA-N 0.000 description 3
- QDSCXUFQYNSNAM-UHFFFAOYSA-N 1-[[4-amino-2-(chloromethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclohexan-1-ol Chemical compound ClCC1=NC=2C(N)=NC3=CC=CC=C3C=2N1CC1(O)CCCCC1 QDSCXUFQYNSNAM-UHFFFAOYSA-N 0.000 description 3
- RTXYIHGMYDJHEU-UHFFFAOYSA-N 2,4-dichloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=C(Cl)C=CN=C1Cl RTXYIHGMYDJHEU-UHFFFAOYSA-N 0.000 description 3
- GSLTVFIVJMCNBH-UHFFFAOYSA-N 2-isocyanatopropane Chemical compound CC(C)N=C=O GSLTVFIVJMCNBH-UHFFFAOYSA-N 0.000 description 3
- JIDPHLLCKDISON-UHFFFAOYSA-N 2h-pyran-4-ol Chemical compound OC1=CCOC=C1 JIDPHLLCKDISON-UHFFFAOYSA-N 0.000 description 3
- FDOIXMGDTOEUQL-UHFFFAOYSA-N 4-chloro-3-nitro-1,5-naphthyridine Chemical compound C1=CC=NC2=C(Cl)C([N+](=O)[O-])=CN=C21 FDOIXMGDTOEUQL-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- XQQPGLWXGOJSKA-UHFFFAOYSA-N 8-[[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]-1,4-dioxaspiro[4.5]decan-8-ol Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CC(CC1)(O)CCC21OCCO2 XQQPGLWXGOJSKA-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 125000003158 alcohol group Chemical group 0.000 description 3
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 3
- 229910000085 borane Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- YOXHCYXIAVIFCZ-UHFFFAOYSA-N cyclopropanol Chemical compound OC1CC1 YOXHCYXIAVIFCZ-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- AFMDCFOWHWNQBP-UHFFFAOYSA-N ethyl 2-(dibenzylamino)acetate Chemical compound C=1C=CC=CC=1CN(CC(=O)OCC)CC1=CC=CC=C1 AFMDCFOWHWNQBP-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 229940047122 interleukins Drugs 0.000 description 3
- 150000002540 isothiocyanates Chemical class 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 3
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 3
- 229910003446 platinum oxide Inorganic materials 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- ARXOYSZUJBSQDM-UHFFFAOYSA-N tert-butyl 4-[[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]-4-hydroxypiperidine-1-carboxylate Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CC1(O)CCN(C(=O)OC(C)(C)C)CC1 ARXOYSZUJBSQDM-UHFFFAOYSA-N 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 150000003509 tertiary alcohols Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 125000002827 triflate group Chemical class FC(S(=O)(=O)O*)(F)F 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 2
- XUXVVQKJULMMKX-UHFFFAOYSA-N 1,1,1-trimethoxypentane Chemical compound CCCCC(OC)(OC)OC XUXVVQKJULMMKX-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- NPPUADHLTOJYKK-UHFFFAOYSA-N 1-(1-methoxycyclohexyl)-2-propylimidazo[4,5-c][1,5]naphthyridin-4-amine Chemical compound CCCC1=NC2=C(N)N=C3C=CC=NC3=C2N1C1(OC)CCCCC1 NPPUADHLTOJYKK-UHFFFAOYSA-N 0.000 description 2
- UHORUBYOVZVQKT-UHFFFAOYSA-N 1-(2-aminoethyl)cyclopropan-1-ol Chemical compound NCCC1(O)CC1 UHORUBYOVZVQKT-UHFFFAOYSA-N 0.000 description 2
- WSIGGNHFHXPCIJ-UHFFFAOYSA-N 1-(aminomethyl)cyclohexan-1-amine;dihydrochloride Chemical compound Cl.Cl.NCC1(N)CCCCC1 WSIGGNHFHXPCIJ-UHFFFAOYSA-N 0.000 description 2
- UFRDYBOWVGFYJB-UHFFFAOYSA-N 1-(nitromethyl)cyclobutan-1-ol Chemical compound [O-][N+](=O)CC1(O)CCC1 UFRDYBOWVGFYJB-UHFFFAOYSA-N 0.000 description 2
- BORHRVRLEZGVIM-UHFFFAOYSA-N 1-(nitromethyl)cyclopentan-1-ol Chemical compound [O-][N+](=O)CC1(O)CCCC1 BORHRVRLEZGVIM-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- UMVTWACRCMSNLN-UHFFFAOYSA-N 1-[(4-amino-2-ethylimidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]cyclopropan-1-ol Chemical compound CCC1=NC2=C(N)N=C3C=CC=NC3=C2N1CC1(O)CC1 UMVTWACRCMSNLN-UHFFFAOYSA-N 0.000 description 2
- HOBAPPWIPRSTDE-UHFFFAOYSA-N 1-[(4-amino-2-methylimidazo[4,5-c]quinolin-1-yl)methyl]cyclobutan-1-ol Chemical compound CC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCC1 HOBAPPWIPRSTDE-UHFFFAOYSA-N 0.000 description 2
- ACHLSHUFVZZWTJ-UHFFFAOYSA-N 1-[(4-amino-2-methylimidazo[4,5-c]quinolin-1-yl)methyl]cyclohexan-1-ol Chemical compound CC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCCCC1 ACHLSHUFVZZWTJ-UHFFFAOYSA-N 0.000 description 2
- MCINRURJDOZTCP-UHFFFAOYSA-N 1-[(4-amino-2-propyl-6,7,8,9-tetrahydroimidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]cyclopentan-1-ol Chemical compound CCCC1=NC2=C(N)N=C3CCCNC3=C2N1CC1(O)CCCC1 MCINRURJDOZTCP-UHFFFAOYSA-N 0.000 description 2
- OKSXWLLAULQKKC-UHFFFAOYSA-N 1-[(4-amino-2-propylimidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]cyclopentan-1-ol Chemical compound CCCC1=NC2=C(N)N=C3C=CC=NC3=C2N1CC1(O)CCCC1 OKSXWLLAULQKKC-UHFFFAOYSA-N 0.000 description 2
- GNSZRKVUZUPOIU-UHFFFAOYSA-N 1-[(4-amino-2-propylimidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]cyclopropan-1-ol Chemical compound CCCC1=NC2=C(N)N=C3C=CC=NC3=C2N1CC1(O)CC1 GNSZRKVUZUPOIU-UHFFFAOYSA-N 0.000 description 2
- NCUBYOWTMOCFKB-UHFFFAOYSA-N 1-[(4-amino-6,7-dimethyl-2-propylimidazo[4,5-c]pyridin-1-yl)methyl]cyclobutan-1-ol Chemical compound CCCC1=NC2=C(N)N=C(C)C(C)=C2N1CC1(O)CCC1 NCUBYOWTMOCFKB-UHFFFAOYSA-N 0.000 description 2
- DBUASXQVHQENAD-UHFFFAOYSA-N 1-[(4-amino-6,7-dimethyl-2-propylimidazo[4,5-c]pyridin-1-yl)methyl]cyclohexan-1-ol Chemical compound CCCC1=NC2=C(N)N=C(C)C(C)=C2N1CC1(O)CCCCC1 DBUASXQVHQENAD-UHFFFAOYSA-N 0.000 description 2
- QRKVEHCFWFUXMJ-UHFFFAOYSA-N 1-[(4-aminoimidazo[4,5-c]quinolin-1-yl)methyl]cyclobutan-1-ol Chemical compound C1=NC=2C(N)=NC3=CC=CC=C3C=2N1CC1(O)CCC1 QRKVEHCFWFUXMJ-UHFFFAOYSA-N 0.000 description 2
- NUQPXJMVJRBSGM-UHFFFAOYSA-N 1-[(4-chloro-2-propylimidazo[4,5-c]quinolin-1-yl)methyl]cyclobutan-1-ol Chemical compound CCCC1=NC2=C(Cl)N=C3C=CC=CC3=C2N1CC1(O)CCC1 NUQPXJMVJRBSGM-UHFFFAOYSA-N 0.000 description 2
- VVBNPSHMCCTHJX-UHFFFAOYSA-N 1-[2-(4-amino-2-methylimidazo[4,5-c]quinolin-1-yl)ethyl]cyclopropan-1-ol Chemical compound CC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCC1(O)CC1 VVBNPSHMCCTHJX-UHFFFAOYSA-N 0.000 description 2
- WNZHHHQDNZDTCP-UHFFFAOYSA-N 1-[2-(4-amino-2-propylimidazo[4,5-c]quinolin-1-yl)ethyl]cyclohexan-1-ol Chemical compound CCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCC1(O)CCCCC1 WNZHHHQDNZDTCP-UHFFFAOYSA-N 0.000 description 2
- ZXDZVERSDOMZHA-UHFFFAOYSA-N 1-[2-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]ethyl]cyclohexan-1-ol Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCC1(O)CCCCC1 ZXDZVERSDOMZHA-UHFFFAOYSA-N 0.000 description 2
- FFZGAYUQQLZOME-UHFFFAOYSA-N 1-[2-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]ethyl]cyclopropan-1-ol Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCC1(O)CC1 FFZGAYUQQLZOME-UHFFFAOYSA-N 0.000 description 2
- IKBBJYGVTOJGIL-UHFFFAOYSA-N 1-[3-(4-amino-2-propylimidazo[4,5-c]quinolin-1-yl)propyl]cyclohexan-1-ol Chemical compound CCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCC1(O)CCCCC1 IKBBJYGVTOJGIL-UHFFFAOYSA-N 0.000 description 2
- IZKUCZQUXWNXGE-UHFFFAOYSA-N 1-[3-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]propyl]cyclohexan-1-ol Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCC1(O)CCCCC1 IZKUCZQUXWNXGE-UHFFFAOYSA-N 0.000 description 2
- NZVDSMJMIVUTKN-UHFFFAOYSA-N 1-[4-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]-4-(2-methylsulfonylethoxy)piperidin-1-yl]ethanone Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(OCCS(C)(=O)=O)CCN(C(C)=O)CC1 NZVDSMJMIVUTKN-UHFFFAOYSA-N 0.000 description 2
- RRAYPGCZLBQJDN-UHFFFAOYSA-N 1-[[(2-chloro-5,6-dimethyl-3-nitropyridin-4-yl)amino]methyl]cyclohexan-1-ol Chemical compound CC1=NC(Cl)=C([N+]([O-])=O)C(NCC2(O)CCCCC2)=C1C RRAYPGCZLBQJDN-UHFFFAOYSA-N 0.000 description 2
- LNLNXIZDDYOCQD-UHFFFAOYSA-N 1-[[(3-aminoquinolin-4-yl)amino]methyl]cyclohexan-1-ol Chemical compound NC1=CN=C2C=CC=CC2=C1NCC1(O)CCCCC1 LNLNXIZDDYOCQD-UHFFFAOYSA-N 0.000 description 2
- NSSGBEGUHIHECL-UHFFFAOYSA-N 1-[[(3-aminoquinolin-4-yl)amino]methyl]cyclopropan-1-ol Chemical compound NC1=CN=C2C=CC=CC2=C1NCC1(O)CC1 NSSGBEGUHIHECL-UHFFFAOYSA-N 0.000 description 2
- HKDXGTDVUVVEGG-UHFFFAOYSA-N 1-[[(3-nitro-1,5-naphthyridin-4-yl)amino]methyl]cyclohexan-1-ol Chemical compound [O-][N+](=O)C=1C=NC2=CC=CN=C2C=1NCC1(O)CCCCC1 HKDXGTDVUVVEGG-UHFFFAOYSA-N 0.000 description 2
- ZWVSAAKVTUGQFR-UHFFFAOYSA-N 1-[[(3-nitroquinolin-4-yl)amino]methyl]cyclobutan-1-ol Chemical compound [O-][N+](=O)C=1C=NC2=CC=CC=C2C=1NCC1(O)CCC1 ZWVSAAKVTUGQFR-UHFFFAOYSA-N 0.000 description 2
- AJPFPTNCVOTWRH-UHFFFAOYSA-N 1-[[(3-nitroquinolin-4-yl)amino]methyl]cyclopentan-1-ol Chemical compound [O-][N+](=O)C=1C=NC2=CC=CC=C2C=1NCC1(O)CCCC1 AJPFPTNCVOTWRH-UHFFFAOYSA-N 0.000 description 2
- CMLYNYVNXSKHQY-UHFFFAOYSA-N 1-[[2-(ethoxymethyl)imidazo[4,5-c][1,5]naphthyridin-1-yl]methyl]cyclohexan-1-ol Chemical compound CCOCC1=NC2=CN=C3C=CC=NC3=C2N1CC1(O)CCCCC1 CMLYNYVNXSKHQY-UHFFFAOYSA-N 0.000 description 2
- FLKAWAFNTSAVJS-UHFFFAOYSA-N 1-[[4-(dibenzylamino)-2-(ethoxymethyl)-6,7-dimethylimidazo[4,5-c]pyridin-1-yl]methyl]cyclohexan-1-ol Chemical compound CCOCC1=NC2=C(N(CC=3C=CC=CC=3)CC=3C=CC=CC=3)N=C(C)C(C)=C2N1CC1(O)CCCCC1 FLKAWAFNTSAVJS-UHFFFAOYSA-N 0.000 description 2
- AJAGZBSDHNKXKZ-UHFFFAOYSA-N 1-[[4-amino-2-(chloromethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclobutan-1-ol Chemical compound ClCC1=NC=2C(N)=NC3=CC=CC=C3C=2N1CC1(O)CCC1 AJAGZBSDHNKXKZ-UHFFFAOYSA-N 0.000 description 2
- PCGYREPASPCJJF-UHFFFAOYSA-N 1-[[4-amino-2-(ethoxymethyl)-6,7-dimethylimidazo[4,5-c]pyridin-1-yl]methyl]cyclobutan-1-ol Chemical compound CCOCC1=NC2=C(N)N=C(C)C(C)=C2N1CC1(O)CCC1 PCGYREPASPCJJF-UHFFFAOYSA-N 0.000 description 2
- FLJQYCOTUJLGSN-UHFFFAOYSA-N 1-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c][1,5]naphthyridin-1-yl]methyl]cyclobutan-1-ol Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=NC3=C2N1CC1(O)CCC1 FLJQYCOTUJLGSN-UHFFFAOYSA-N 0.000 description 2
- IVXUYBUKAFFWBF-UHFFFAOYSA-N 1-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c][1,5]naphthyridin-1-yl]methyl]cyclohexan-1-ol Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=NC3=C2N1CC1(O)CCCCC1 IVXUYBUKAFFWBF-UHFFFAOYSA-N 0.000 description 2
- HWBJXBIUTJFZPT-UHFFFAOYSA-N 1-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclobutan-1-ol Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCC1 HWBJXBIUTJFZPT-UHFFFAOYSA-N 0.000 description 2
- QOKHQNOTMQXTQZ-UHFFFAOYSA-N 1-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclopropan-1-ol Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CC1 QOKHQNOTMQXTQZ-UHFFFAOYSA-N 0.000 description 2
- RPOAINYPQNKLKR-UHFFFAOYSA-N 1-[[4-amino-2-(hydroxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclobutan-1-ol Chemical compound OCC1=NC=2C(N)=NC3=CC=CC=C3C=2N1CC1(O)CCC1 RPOAINYPQNKLKR-UHFFFAOYSA-N 0.000 description 2
- YMKWTWVPHJHFNS-UHFFFAOYSA-N 1-[[4-amino-2-(hydroxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclohexan-1-ol Chemical compound OCC1=NC=2C(N)=NC3=CC=CC=C3C=2N1CC1(O)CCCCC1 YMKWTWVPHJHFNS-UHFFFAOYSA-N 0.000 description 2
- REUXKAQNJDAQJE-UHFFFAOYSA-N 1-[[[2-(dibenzylamino)-5,6-dimethyl-3-nitropyridin-4-yl]amino]methyl]cyclohexan-1-ol Chemical compound [O-][N+](=O)C=1C(NCC2(O)CCCCC2)=C(C)C(C)=NC=1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 REUXKAQNJDAQJE-UHFFFAOYSA-N 0.000 description 2
- HUMMCZRNZCKXHL-UHFFFAOYSA-N 1-aminocyclohexane-1-carbonitrile Chemical compound N#CC1(N)CCCCC1 HUMMCZRNZCKXHL-UHFFFAOYSA-N 0.000 description 2
- WUIJTQZXUURFQU-UHFFFAOYSA-N 1-methylsulfonylethene Chemical compound CS(=O)(=O)C=C WUIJTQZXUURFQU-UHFFFAOYSA-N 0.000 description 2
- ZSLKGUQYEQVKQE-UHFFFAOYSA-N 1-prop-2-enylcyclohexan-1-ol Chemical compound C=CCC1(O)CCCCC1 ZSLKGUQYEQVKQE-UHFFFAOYSA-N 0.000 description 2
- UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical class NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 description 2
- CEGLXJGCOGYSFS-UHFFFAOYSA-N 2,4-dichloro-5,6-dimethyl-3-nitropyridine Chemical compound CC1=NC(Cl)=C([N+]([O-])=O)C(Cl)=C1C CEGLXJGCOGYSFS-UHFFFAOYSA-N 0.000 description 2
- VKIFKIOUKFOASD-UHFFFAOYSA-N 2-(ethoxymethyl)-1-[(1-methoxycyclopentyl)methyl]imidazo[4,5-c]quinolin-4-amine Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(OC)CCCC1 VKIFKIOUKFOASD-UHFFFAOYSA-N 0.000 description 2
- UUOLETYDNTVQDY-UHFFFAOYSA-N 2-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1Cl UUOLETYDNTVQDY-UHFFFAOYSA-N 0.000 description 2
- ULQQGOGMQRGFFR-UHFFFAOYSA-N 2-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=CC=C1Cl ULQQGOGMQRGFFR-UHFFFAOYSA-N 0.000 description 2
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- FWDYVLKHYYQFGA-UHFFFAOYSA-N 3-[1-[tert-butyl(dimethyl)silyl]oxycyclohexyl]propan-1-amine Chemical compound CC(C)(C)[Si](C)(C)OC1(CCCN)CCCCC1 FWDYVLKHYYQFGA-UHFFFAOYSA-N 0.000 description 2
- WNKMDJZQSYQGJK-UHFFFAOYSA-N 3-[1-[tert-butyl(dimethyl)silyl]oxycyclohexyl]propan-1-ol Chemical compound CC(C)(C)[Si](C)(C)OC1(CCCO)CCCCC1 WNKMDJZQSYQGJK-UHFFFAOYSA-N 0.000 description 2
- PBKXSAQAZBNXNT-UHFFFAOYSA-N 3-[1-[tert-butyl(dimethyl)silyl]oxycyclohexyl]propyl methanesulfonate Chemical compound CS(=O)(=O)OCCCC1(O[Si](C)(C)C(C)(C)C)CCCCC1 PBKXSAQAZBNXNT-UHFFFAOYSA-N 0.000 description 2
- JSMDUOFOPDSKIQ-UHFFFAOYSA-N 3-methoxypropanoyl chloride Chemical compound COCCC(Cl)=O JSMDUOFOPDSKIQ-UHFFFAOYSA-N 0.000 description 2
- HVAGLCLPZYKTQQ-UHFFFAOYSA-N 4-(nitromethyl)oxan-4-ol Chemical compound [O-][N+](=O)CC1(O)CCOCC1 HVAGLCLPZYKTQQ-UHFFFAOYSA-N 0.000 description 2
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- QMQWFCWNCQZZIX-UHFFFAOYSA-N 4-[(4-amino-2-ethylimidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]oxan-4-ol Chemical compound CCC1=NC2=C(N)N=C3C=CC=NC3=C2N1CC1(O)CCOCC1 QMQWFCWNCQZZIX-UHFFFAOYSA-N 0.000 description 2
- SMRIKXUKFHNOHZ-UHFFFAOYSA-N 4-[(4-amino-2-ethylimidazo[4,5-c]quinolin-1-yl)methyl]oxan-4-ol Chemical compound CCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCOCC1 SMRIKXUKFHNOHZ-UHFFFAOYSA-N 0.000 description 2
- ZIWZFHFYMAWHKZ-UHFFFAOYSA-N 4-[(4-amino-2-propylimidazo[4,5-c]quinolin-1-yl)methyl]oxan-4-ol Chemical compound CCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCOCC1 ZIWZFHFYMAWHKZ-UHFFFAOYSA-N 0.000 description 2
- XVSYWWAKDBOYFW-UHFFFAOYSA-N 4-[(4-aminoimidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]oxan-4-ol Chemical compound C1=NC=2C(N)=NC3=CC=CN=C3C=2N1CC1(O)CCOCC1 XVSYWWAKDBOYFW-UHFFFAOYSA-N 0.000 description 2
- DIWVJHHZCKZHIN-UHFFFAOYSA-N 4-[2-(4-amino-2-propylimidazo[4,5-c]quinolin-1-yl)ethyl]oxan-4-ol Chemical compound CCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCC1(O)CCOCC1 DIWVJHHZCKZHIN-UHFFFAOYSA-N 0.000 description 2
- VHGHHUYSIWDFOY-UHFFFAOYSA-N 4-[[(3-amino-1,5-naphthyridin-4-yl)amino]methyl]oxan-4-ol Chemical compound NC1=CN=C2C=CC=NC2=C1NCC1(O)CCOCC1 VHGHHUYSIWDFOY-UHFFFAOYSA-N 0.000 description 2
- ONXUZOWZBGAAIL-UHFFFAOYSA-N 4-[[(3-nitroquinolin-4-yl)amino]methyl]oxan-4-ol Chemical compound [O-][N+](=O)C=1C=NC2=CC=CC=C2C=1NCC1(O)CCOCC1 ONXUZOWZBGAAIL-UHFFFAOYSA-N 0.000 description 2
- DZCSODIENATSOR-UHFFFAOYSA-N 4-[[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]oxan-4-ol Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CC1(O)CCOCC1 DZCSODIENATSOR-UHFFFAOYSA-N 0.000 description 2
- RZXHAJFRBLLWNF-UHFFFAOYSA-N 4-[[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]piperidin-4-ol Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CC1(O)CCNCC1 RZXHAJFRBLLWNF-UHFFFAOYSA-N 0.000 description 2
- BJZOWVMZSMQHQU-UHFFFAOYSA-N 4-[[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]methyl]oxan-4-ol Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCOCC1 BJZOWVMZSMQHQU-UHFFFAOYSA-N 0.000 description 2
- JGFSLWFEJMPCDT-UHFFFAOYSA-N 4-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]-1-methylsulfonylpiperidin-4-ol Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCN(S(C)(=O)=O)CC1 JGFSLWFEJMPCDT-UHFFFAOYSA-N 0.000 description 2
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical class C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- LXJYSQGCJGEDBZ-UHFFFAOYSA-N 8-(aminomethyl)-1,4-dioxaspiro[4.5]decan-8-ol Chemical compound C1CC(CN)(O)CCC21OCCO2 LXJYSQGCJGEDBZ-UHFFFAOYSA-N 0.000 description 2
- HUDVAVREBBQAOY-UHFFFAOYSA-N 8-(nitromethyl)-1,4-dioxaspiro[4.5]decan-8-ol Chemical compound C1CC(O)(C[N+]([O-])=O)CCC21OCCO2 HUDVAVREBBQAOY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 229910017974 NH40H Inorganic materials 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000003152 Yellow Fever Diseases 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 2
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 2
- BBDKGMMFFHIING-UHFFFAOYSA-N ethyl 3-(dibenzylamino)propanoate Chemical compound C=1C=CC=CC=1CN(CCC(=O)OCC)CC1=CC=CC=C1 BBDKGMMFFHIING-UHFFFAOYSA-N 0.000 description 2
- MEHDPHFVOFBZMT-UHFFFAOYSA-N ethyl 4-(aminomethyl)-4-hydroxypiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(O)(CN)CC1 MEHDPHFVOFBZMT-UHFFFAOYSA-N 0.000 description 2
- LFPDKXBNISSQKO-UHFFFAOYSA-N ethyl 4-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]-4-hydroxypiperidine-1-carboxylate Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCN(C(=O)OCC)CC1 LFPDKXBNISSQKO-UHFFFAOYSA-N 0.000 description 2
- REWMGYLEJYCGAM-UHFFFAOYSA-N ethyl 4-hydroxy-4-(nitromethyl)piperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(O)(C[N+]([O-])=O)CC1 REWMGYLEJYCGAM-UHFFFAOYSA-N 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 2
- DQEUYIQDSMINEY-UHFFFAOYSA-M magnesium;prop-1-ene;bromide Chemical compound [Mg+2].[Br-].[CH2-]C=C DQEUYIQDSMINEY-UHFFFAOYSA-M 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- LWIBIVLIPFTPFC-UHFFFAOYSA-N n-[(1-aminocyclohexyl)methyl]-3-nitroquinolin-4-amine Chemical compound [O-][N+](=O)C=1C=NC2=CC=CC=C2C=1NCC1(N)CCCCC1 LWIBIVLIPFTPFC-UHFFFAOYSA-N 0.000 description 2
- RNZIVWRWKFCVCS-UHFFFAOYSA-N n-[1-[[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclohexyl]methanesulfonamide Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CC1(NS(C)(=O)=O)CCCCC1 RNZIVWRWKFCVCS-UHFFFAOYSA-N 0.000 description 2
- WDWYNJRWNXBTJJ-UHFFFAOYSA-N n-[1-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclohexyl]methanesulfonamide Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(NS(C)(=O)=O)CCCCC1 WDWYNJRWNXBTJJ-UHFFFAOYSA-N 0.000 description 2
- YVJDSNJBFUZDKA-UHFFFAOYSA-N n-[[4-amino-1-[(1-hydroxycyclohexyl)methyl]imidazo[4,5-c]quinolin-2-yl]methyl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NCC1=NC=2C(N)=NC3=CC=CC=C3C=2N1CC1(O)CCCCC1 YVJDSNJBFUZDKA-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- 150000002905 orthoesters Chemical class 0.000 description 2
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- 150000003138 primary alcohols Chemical class 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- LZMATGARSSLFMQ-UHFFFAOYSA-N propan-2-ylurea Chemical compound CC(C)NC(N)=O LZMATGARSSLFMQ-UHFFFAOYSA-N 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- XYWCDAFPRBDRER-UHFFFAOYSA-N tert-butyl 4-(aminomethyl)-4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)(CN)CC1 XYWCDAFPRBDRER-UHFFFAOYSA-N 0.000 description 2
- JGJOYHKORNPHGO-UHFFFAOYSA-N tert-butyl 4-[[(3-aminoquinolin-4-yl)amino]methyl]-4-hydroxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(O)CNC1=C(N)C=NC2=CC=CC=C12 JGJOYHKORNPHGO-UHFFFAOYSA-N 0.000 description 2
- DBHFQZMFKNTFPT-UHFFFAOYSA-N tert-butyl 4-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]-4-hydroxypiperidine-1-carboxylate Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCN(C(=O)OC(C)(C)C)CC1 DBHFQZMFKNTFPT-UHFFFAOYSA-N 0.000 description 2
- AJNCHUMJVPZDCG-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-(nitromethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)(C[N+]([O-])=O)CC1 AJNCHUMJVPZDCG-UHFFFAOYSA-N 0.000 description 2
- IZKWBNMQQHJFGM-UHFFFAOYSA-N tert-butyl n-[1-[[(3-aminoquinolin-4-yl)amino]methyl]cyclohexyl]carbamate Chemical compound NC=1C=NC2=CC=CC=C2C=1NCC1(NC(=O)OC(C)(C)C)CCCCC1 IZKWBNMQQHJFGM-UHFFFAOYSA-N 0.000 description 2
- MQXHTRHTVPNRQJ-UHFFFAOYSA-N tert-butyl n-[1-[[(3-nitroquinolin-4-yl)amino]methyl]cyclohexyl]carbamate Chemical compound [O-][N+](=O)C=1C=NC2=CC=CC=C2C=1NCC1(NC(=O)OC(C)(C)C)CCCCC1 MQXHTRHTVPNRQJ-UHFFFAOYSA-N 0.000 description 2
- QCIWZIYBBNEPKB-UHFFFAOYSA-N tert-butyl(dimethyl)silane Chemical compound C[SiH](C)C(C)(C)C QCIWZIYBBNEPKB-UHFFFAOYSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000012646 vaccine adjuvant Substances 0.000 description 2
- 229940124931 vaccine adjuvant Drugs 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- LSRVEPKOAZIZPE-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridin-4-amine Chemical class C1=CC=C2C(N)CCNC2=N1 LSRVEPKOAZIZPE-UHFFFAOYSA-N 0.000 description 1
- UZAOPTDGCXICDB-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinolin-4-amine Chemical class C1=CC=C2C(N)CCNC2=C1 UZAOPTDGCXICDB-UHFFFAOYSA-N 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- VKRKCBWIVLSRBJ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)CCC21OCCO2 VKRKCBWIVLSRBJ-UHFFFAOYSA-N 0.000 description 1
- 125000005962 1,4-oxazepanyl group Chemical group 0.000 description 1
- 150000005055 1,5-naphthyridines Chemical class 0.000 description 1
- YJKZDGOMTKOYQK-UHFFFAOYSA-N 1-(2-piperidin-4-ylethyl)imidazo[4,5-c]quinoline Chemical compound C1=NC2=CN=C3C=CC=CC3=C2N1CCC1CCNCC1 YJKZDGOMTKOYQK-UHFFFAOYSA-N 0.000 description 1
- JXJORHGRCCODBV-UHFFFAOYSA-N 1-(aminomethyl)cyclopropan-1-ol Chemical compound NCC1(O)CC1 JXJORHGRCCODBV-UHFFFAOYSA-N 0.000 description 1
- VCBYEQBFSSCIQJ-UHFFFAOYSA-N 1-(ethoxymethyl)imidazo[4,5-c]quinoline Chemical compound C1=CC=CC2=C3N(COCC)C=NC3=CN=C21 VCBYEQBFSSCIQJ-UHFFFAOYSA-N 0.000 description 1
- CKZFCCAINCLTIL-UHFFFAOYSA-N 1-[(2-methylimidazo[4,5-c]quinolin-1-yl)methyl]cyclohexan-1-ol Chemical compound CC1=NC2=CN=C3C=CC=CC3=C2N1CC1(O)CCCCC1 CKZFCCAINCLTIL-UHFFFAOYSA-N 0.000 description 1
- FGGAPCGVBJRFRB-UHFFFAOYSA-N 1-[(2-propylimidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]cyclohexan-1-ol Chemical compound CCCC1=NC2=CN=C3C=CC=NC3=C2N1CC1(O)CCCCC1 FGGAPCGVBJRFRB-UHFFFAOYSA-N 0.000 description 1
- XZSGFEQHOZKSRO-UHFFFAOYSA-N 1-[(4-amino-2,6,7-trimethylimidazo[4,5-c]pyridin-1-yl)methyl]cyclobutan-1-ol Chemical compound CC1=NC2=C(N)N=C(C)C(C)=C2N1CC1(O)CCC1 XZSGFEQHOZKSRO-UHFFFAOYSA-N 0.000 description 1
- MYBXZSFOMBVWQL-UHFFFAOYSA-N 1-[(4-amino-2-propylimidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]cyclohexan-1-ol Chemical compound CCCC1=NC2=C(N)N=C3C=CC=NC3=C2N1CC1(O)CCCCC1 MYBXZSFOMBVWQL-UHFFFAOYSA-N 0.000 description 1
- FZVXLZVLAJLNFL-UHFFFAOYSA-N 1-[(4-amino-2-propylimidazo[4,5-c]quinolin-1-yl)methyl]cyclobutan-1-ol Chemical compound CCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCC1 FZVXLZVLAJLNFL-UHFFFAOYSA-N 0.000 description 1
- GQCCIMOHQFVWCW-UHFFFAOYSA-N 1-[(4-aminoimidazo[4,5-c]quinolin-1-yl)methyl]cyclohexan-1-ol Chemical compound C1=NC=2C(N)=NC3=CC=CC=C3C=2N1CC1(O)CCCCC1 GQCCIMOHQFVWCW-UHFFFAOYSA-N 0.000 description 1
- ZVVNOPWOHHMEQL-UHFFFAOYSA-N 1-[1-[[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclohexyl]-3-propan-2-ylurea Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CC1(NC(=O)NC(C)C)CCCCC1 ZVVNOPWOHHMEQL-UHFFFAOYSA-N 0.000 description 1
- CCEVSNRMURGTKU-UHFFFAOYSA-N 1-[1-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclohexyl]-1-propan-2-ylurea Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(N(C(C)C)C(N)=O)CCCCC1 CCEVSNRMURGTKU-UHFFFAOYSA-N 0.000 description 1
- SOSMGPAAEJANJN-UHFFFAOYSA-N 1-[2-(2-ethylimidazo[4,5-c]quinolin-1-yl)ethyl]cyclopropan-1-ol Chemical compound CCC1=NC2=CN=C3C=CC=CC3=C2N1CCC1(O)CC1 SOSMGPAAEJANJN-UHFFFAOYSA-N 0.000 description 1
- JRGVNLNJSSJCLX-UHFFFAOYSA-N 1-[2-(4-amino-2-ethylimidazo[4,5-c]quinolin-1-yl)ethyl]cyclopropan-1-ol Chemical compound CCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCC1(O)CC1 JRGVNLNJSSJCLX-UHFFFAOYSA-N 0.000 description 1
- BPDGHTNVOYBQPH-UHFFFAOYSA-N 1-[2-(4-amino-2-methylimidazo[4,5-c]quinolin-1-yl)ethyl]cyclohexan-1-ol Chemical compound CC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCC1(O)CCCCC1 BPDGHTNVOYBQPH-UHFFFAOYSA-N 0.000 description 1
- VXKDQBUZSZGESV-UHFFFAOYSA-N 1-[2-(dibenzylamino)ethyl]cyclopropan-1-ol Chemical compound C=1C=CC=CC=1CN(CC=1C=CC=CC=1)CCC1(O)CC1 VXKDQBUZSZGESV-UHFFFAOYSA-N 0.000 description 1
- LTAJRDYGXFEZRL-UHFFFAOYSA-N 1-[2-[(3-nitroquinolin-4-yl)amino]ethyl]cyclopropan-1-ol Chemical compound [O-][N+](=O)C=1C=NC2=CC=CC=C2C=1NCCC1(O)CC1 LTAJRDYGXFEZRL-UHFFFAOYSA-N 0.000 description 1
- LKVPDHUDSIPNQS-UHFFFAOYSA-N 1-[2-[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]ethyl]cyclopropan-1-ol Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CCC1(O)CC1 LKVPDHUDSIPNQS-UHFFFAOYSA-N 0.000 description 1
- ABJMONGPQSBKOI-UHFFFAOYSA-N 1-[3-(4-amino-2-methylimidazo[4,5-c]quinolin-1-yl)propyl]cyclopropan-1-ol Chemical compound CC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCC1(O)CC1 ABJMONGPQSBKOI-UHFFFAOYSA-N 0.000 description 1
- AVGIZPWNVUXSLH-UHFFFAOYSA-N 1-[3-[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]propyl]cyclohexan-1-ol Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CCCC1(O)CCCCC1 AVGIZPWNVUXSLH-UHFFFAOYSA-N 0.000 description 1
- JVJMTRVDFJISES-UHFFFAOYSA-N 1-[4-[[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]-4-(2-methylsulfonylethoxy)piperidin-1-yl]ethanone Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CC1(OCCS(C)(=O)=O)CCN(C(C)=O)CC1 JVJMTRVDFJISES-UHFFFAOYSA-N 0.000 description 1
- QMPDPPZINVLMPH-UHFFFAOYSA-N 1-[[(3-aminoquinolin-4-yl)amino]methyl]cyclobutan-1-ol Chemical compound NC1=CN=C2C=CC=CC2=C1NCC1(O)CCC1 QMPDPPZINVLMPH-UHFFFAOYSA-N 0.000 description 1
- ABAYXPDXUHPOJV-UHFFFAOYSA-N 1-[[(3-aminoquinolin-4-yl)amino]methyl]cyclopentan-1-ol Chemical compound NC1=CN=C2C=CC=CC2=C1NCC1(O)CCCC1 ABAYXPDXUHPOJV-UHFFFAOYSA-N 0.000 description 1
- VCHCXRBHJKJNCM-UHFFFAOYSA-N 1-[[(3-aminoquinolin-4-yl)amino]methyl]cyclopentan-1-ol;dichloromethane Chemical compound ClCCl.NC1=CN=C2C=CC=CC2=C1NCC1(O)CCCC1 VCHCXRBHJKJNCM-UHFFFAOYSA-N 0.000 description 1
- ACWCVMQOGWDIAS-UHFFFAOYSA-N 1-[[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclobutan-1-ol Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CC1(O)CCC1 ACWCVMQOGWDIAS-UHFFFAOYSA-N 0.000 description 1
- OFCKYYPCUPWJMB-UHFFFAOYSA-N 1-[[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclopentan-1-ol Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CC1(O)CCCC1 OFCKYYPCUPWJMB-UHFFFAOYSA-N 0.000 description 1
- DFEKZVQVPORRAS-UHFFFAOYSA-N 1-[[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclopropan-1-amine;hydrochloride Chemical compound Cl.CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CC1(N)CC1 DFEKZVQVPORRAS-UHFFFAOYSA-N 0.000 description 1
- KCHRVYDXBGDBQE-UHFFFAOYSA-N 1-[[4-(dibenzylamino)-6,7-dimethyl-2-propylimidazo[4,5-c]pyridin-1-yl]methyl]cyclohexan-1-ol Chemical compound CCCC1=NC2=C(N(CC=3C=CC=CC=3)CC=3C=CC=CC=3)N=C(C)C(C)=C2N1CC1(O)CCCCC1 KCHRVYDXBGDBQE-UHFFFAOYSA-N 0.000 description 1
- LDVNPRBAKFWKOA-UHFFFAOYSA-N 1-[[4-amino-2-(ethoxymethyl)-6,7,8,9-tetrahydroimidazo[4,5-c]quinolin-1-yl]methyl]cyclopentan-1-ol Chemical compound CCOCC1=NC2=C(N)N=C3CCCCC3=C2N1CC1(O)CCCC1 LDVNPRBAKFWKOA-UHFFFAOYSA-N 0.000 description 1
- GSXJOYQIIRCYSV-UHFFFAOYSA-N 1-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c][1,5]naphthyridin-1-yl]methyl]cyclopropan-1-ol Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=NC3=C2N1CC1(O)CC1 GSXJOYQIIRCYSV-UHFFFAOYSA-N 0.000 description 1
- GGGZKSVJEXPXFH-UHFFFAOYSA-N 1-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclohexan-1-ol Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCCCC1 GGGZKSVJEXPXFH-UHFFFAOYSA-N 0.000 description 1
- SSNZHPQEXFYTTM-UHFFFAOYSA-N 1-[[4-amino-2-(hydroxymethyl)imidazo[4,5-c][1,5]naphthyridin-1-yl]methyl]cyclobutan-1-ol Chemical compound OCC1=NC=2C(N)=NC3=CC=CN=C3C=2N1CC1(O)CCC1 SSNZHPQEXFYTTM-UHFFFAOYSA-N 0.000 description 1
- HHIRBXHEYVDUAM-UHFFFAOYSA-N 1-chloro-3-isocyanatobenzene Chemical compound ClC1=CC=CC(N=C=O)=C1 HHIRBXHEYVDUAM-UHFFFAOYSA-N 0.000 description 1
- ADAKRBAJFHTIEW-UHFFFAOYSA-N 1-chloro-4-isocyanatobenzene Chemical compound ClC1=CC=C(N=C=O)C=C1 ADAKRBAJFHTIEW-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- QTQLUUDYDWDXNA-UHFFFAOYSA-N 1-ethyl-4-(1-ethylpyridin-1-ium-4-yl)pyridin-1-ium Chemical compound C1=C[N+](CC)=CC=C1C1=CC=[N+](CC)C=C1 QTQLUUDYDWDXNA-UHFFFAOYSA-N 0.000 description 1
- ZXBJDSANDCPCLD-UHFFFAOYSA-L 1-ethyl-4-(1-ethylpyridin-1-ium-4-yl)pyridin-1-ium;diiodide Chemical compound [I-].[I-].C1=C[N+](CC)=CC=C1C1=CC=[N+](CC)C=C1 ZXBJDSANDCPCLD-UHFFFAOYSA-L 0.000 description 1
- NPOVTGVGOBJZPY-UHFFFAOYSA-N 1-isocyanato-3-methoxybenzene Chemical compound COC1=CC=CC(N=C=O)=C1 NPOVTGVGOBJZPY-UHFFFAOYSA-N 0.000 description 1
- CPPGZWWUPFWALU-UHFFFAOYSA-N 1-isocyanato-3-methylbenzene Chemical compound CC1=CC=CC(N=C=O)=C1 CPPGZWWUPFWALU-UHFFFAOYSA-N 0.000 description 1
- GVUBEJANEHZYPA-UHFFFAOYSA-L 1-octyl-4-(1-octylpyridin-1-ium-4-yl)pyridin-1-ium;dibromide Chemical compound [Br-].[Br-].C1=C[N+](CCCCCCCC)=CC=C1C1=CC=[N+](CCCCCCCC)C=C1 GVUBEJANEHZYPA-UHFFFAOYSA-L 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- UWDDPORBSKCZQD-UHFFFAOYSA-N 2-(2-methylsulfonylethoxy)piperidine-1-carboxylic acid Chemical compound CS(=O)(=O)CCOC1CCCCN1C(=O)O UWDDPORBSKCZQD-UHFFFAOYSA-N 0.000 description 1
- LEANCXGFUTZVNL-UHFFFAOYSA-N 2-(dibenzylazaniumyl)propanoate Chemical compound C=1C=CC=CC=1CN(C(C)C(O)=O)CC1=CC=CC=C1 LEANCXGFUTZVNL-UHFFFAOYSA-N 0.000 description 1
- XNPQIXOBJWIACG-UHFFFAOYSA-N 2-(ethoxymethyl)-1-(1-methoxycyclohexyl)imidazo[4,5-c][1,5]naphthyridin-4-amine Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=NC3=C2N1C1(OC)CCCCC1 XNPQIXOBJWIACG-UHFFFAOYSA-N 0.000 description 1
- NOYBYBROZHXDCH-UHFFFAOYSA-N 2-(ethoxymethyl)-1-(1-methoxycyclohexyl)imidazo[4,5-c][1,5]naphthyridine Chemical compound CCOCC1=NC2=CN=C3C=CC=NC3=C2N1C1(OC)CCCCC1 NOYBYBROZHXDCH-UHFFFAOYSA-N 0.000 description 1
- OVOMLBFIHRXJFH-UHFFFAOYSA-N 2-(ethoxymethyl)-1-[(1-methoxycyclopentyl)methyl]imidazo[4,5-c]quinoline Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CC1(OC)CCCC1 OVOMLBFIHRXJFH-UHFFFAOYSA-N 0.000 description 1
- SIRRAQQGGCNHQB-UHFFFAOYSA-N 2-chloro-1h-imidazo[4,5-b]pyridine Chemical compound C1=CC=C2NC(Cl)=NC2=N1 SIRRAQQGGCNHQB-UHFFFAOYSA-N 0.000 description 1
- PQZXGIIGQHCVAU-UHFFFAOYSA-N 2-chloro-3-nitroquinoline Chemical compound C1=CC=C2N=C(Cl)C([N+](=O)[O-])=CC2=C1 PQZXGIIGQHCVAU-UHFFFAOYSA-N 0.000 description 1
- NILLIUYSJFTTRH-UHFFFAOYSA-N 2-cyclopentylacetyl chloride Chemical compound ClC(=O)CC1CCCC1 NILLIUYSJFTTRH-UHFFFAOYSA-N 0.000 description 1
- SQUDOXXJNCERBW-UHFFFAOYSA-N 2-ethoxy-n-[4-[2-(1-hydroxycyclopropyl)ethylamino]quinolin-3-yl]acetamide;hydrochloride Chemical compound Cl.CCOCC(=O)NC1=CN=C2C=CC=CC2=C1NCCC1(O)CC1 SQUDOXXJNCERBW-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- WHIHIKVIWVIIER-UHFFFAOYSA-N 3-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Cl)=C1 WHIHIKVIWVIIER-UHFFFAOYSA-N 0.000 description 1
- RPESZQVUWMFBEO-UHFFFAOYSA-N 3-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(C#N)=C1 RPESZQVUWMFBEO-UHFFFAOYSA-N 0.000 description 1
- RUQIUASLAXJZIE-UHFFFAOYSA-N 3-methoxybenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1 RUQIUASLAXJZIE-UHFFFAOYSA-N 0.000 description 1
- FULSSJUSJYSWAE-UHFFFAOYSA-N 3h-imidazo[4,5-c][1,5]naphthyridin-4-amine Chemical class NC1=NC2=CC=CN=C2C2=C1N=CN2 FULSSJUSJYSWAE-UHFFFAOYSA-N 0.000 description 1
- KGEGVJJFFQXJTG-UHFFFAOYSA-N 3h-imidazo[4,5-c][1,8]naphthyridin-4-amine Chemical compound NC1=NC2=NC=CC=C2C2=C1N=CN2 KGEGVJJFFQXJTG-UHFFFAOYSA-N 0.000 description 1
- ZBNWAYGRNUZHCX-UHFFFAOYSA-N 4-(imidazo[4,5-c][1,5]naphthyridin-1-ylmethyl)oxan-4-ol Chemical compound C1=NC2=CN=C3C=CC=NC3=C2N1CC1(O)CCOCC1 ZBNWAYGRNUZHCX-UHFFFAOYSA-N 0.000 description 1
- CQLIOIITJCEGJF-UHFFFAOYSA-N 4-[(2-ethylimidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]oxan-4-ol Chemical compound CCC1=NC2=CN=C3C=CC=NC3=C2N1CC1(O)CCOCC1 CQLIOIITJCEGJF-UHFFFAOYSA-N 0.000 description 1
- OTCGROPABADPDN-UHFFFAOYSA-N 4-[(2-ethylimidazo[4,5-c]quinolin-1-yl)methyl]oxan-4-ol Chemical compound CCC1=NC2=CN=C3C=CC=CC3=C2N1CC1(O)CCOCC1 OTCGROPABADPDN-UHFFFAOYSA-N 0.000 description 1
- WVMDTOODNGNSBX-UHFFFAOYSA-N 4-[(2-methylimidazo[4,5-c]quinolin-1-yl)methyl]oxan-4-ol Chemical compound CC1=NC2=CN=C3C=CC=CC3=C2N1CC1(O)CCOCC1 WVMDTOODNGNSBX-UHFFFAOYSA-N 0.000 description 1
- FLGKIVSQDRTUPD-UHFFFAOYSA-N 4-[(2-propylimidazo[4,5-c]quinolin-1-yl)methyl]oxan-4-ol Chemical compound CCCC1=NC2=CN=C3C=CC=CC3=C2N1CC1(O)CCOCC1 FLGKIVSQDRTUPD-UHFFFAOYSA-N 0.000 description 1
- XYRZUKZIRPVUPG-UHFFFAOYSA-N 4-[(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)methyl]oxan-4-ol Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCOCC1 XYRZUKZIRPVUPG-UHFFFAOYSA-N 0.000 description 1
- WIZUBLDHZBDUDG-UHFFFAOYSA-N 4-[(4-amino-2-methylimidazo[4,5-c]quinolin-1-yl)methyl]oxan-4-ol Chemical compound CC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCOCC1 WIZUBLDHZBDUDG-UHFFFAOYSA-N 0.000 description 1
- VBVQSUGQGFFSQE-UHFFFAOYSA-N 4-[(4-amino-2-propylimidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]oxan-4-ol Chemical compound CCCC1=NC2=C(N)N=C3C=CC=NC3=C2N1CC1(O)CCOCC1 VBVQSUGQGFFSQE-UHFFFAOYSA-N 0.000 description 1
- MWLSZQMMXZPRKP-UHFFFAOYSA-N 4-[2-(2-ethylimidazo[4,5-c]quinolin-1-yl)ethyl]oxan-4-ol Chemical compound CCC1=NC2=CN=C3C=CC=CC3=C2N1CCC1(O)CCOCC1 MWLSZQMMXZPRKP-UHFFFAOYSA-N 0.000 description 1
- POSIKGZRJGRJLO-UHFFFAOYSA-N 4-[2-(2-methylimidazo[4,5-c]quinolin-1-yl)ethyl]oxan-4-ol Chemical compound CC1=NC2=CN=C3C=CC=CC3=C2N1CCC1(O)CCOCC1 POSIKGZRJGRJLO-UHFFFAOYSA-N 0.000 description 1
- TZVNUCOKDFCWGG-UHFFFAOYSA-N 4-[2-(4-amino-2-ethylimidazo[4,5-c]quinolin-1-yl)ethyl]oxan-4-ol Chemical compound CCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCC1(O)CCOCC1 TZVNUCOKDFCWGG-UHFFFAOYSA-N 0.000 description 1
- JCFFFCQLGAWJPC-UHFFFAOYSA-N 4-[2-(4-amino-2-methylimidazo[4,5-c]quinolin-1-yl)ethyl]oxan-4-ol Chemical compound CC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCC1(O)CCOCC1 JCFFFCQLGAWJPC-UHFFFAOYSA-N 0.000 description 1
- YEPRWDYFYQSGPO-UHFFFAOYSA-N 4-[2-[(3-nitroquinolin-4-yl)amino]ethyl]oxan-4-ol Chemical compound [O-][N+](=O)C=1C=NC2=CC=CC=C2C=1NCCC1(O)CCOCC1 YEPRWDYFYQSGPO-UHFFFAOYSA-N 0.000 description 1
- GDCJPIAJDKZTEF-UHFFFAOYSA-N 4-[[2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]methyl]oxan-4-ol Chemical compound COCCC1=NC2=CN=C3C=CC=CC3=C2N1CC1(O)CCOCC1 GDCJPIAJDKZTEF-UHFFFAOYSA-N 0.000 description 1
- QRGAMOULNHJZTO-UHFFFAOYSA-N 4-[[2-(chloromethyl)imidazo[4,5-c]quinolin-1-yl]methyl]oxan-4-ol Chemical compound ClCC1=NC2=CN=C3C=CC=CC3=C2N1CC1(O)CCOCC1 QRGAMOULNHJZTO-UHFFFAOYSA-N 0.000 description 1
- YXIZJZHHUDNEMY-UHFFFAOYSA-N 4-[[2-(ethoxymethyl)imidazo[4,5-c][1,5]naphthyridin-1-yl]methyl]oxan-4-ol Chemical compound CCOCC1=NC2=CN=C3C=CC=NC3=C2N1CC1(O)CCOCC1 YXIZJZHHUDNEMY-UHFFFAOYSA-N 0.000 description 1
- DTHMZBIOXAAEOK-UHFFFAOYSA-N 4-[[4-amino-2-(2-hydroxyethyl)imidazo[4,5-c][1,5]naphthyridin-1-yl]methyl]oxan-4-ol Chemical compound OCCC1=NC=2C(N)=NC3=CC=CN=C3C=2N1CC1(O)CCOCC1 DTHMZBIOXAAEOK-UHFFFAOYSA-N 0.000 description 1
- GDPKTEKIQSSWSV-UHFFFAOYSA-N 4-[[4-amino-2-(2-hydroxyethyl)imidazo[4,5-c]quinolin-1-yl]methyl]oxan-4-ol Chemical compound OCCC1=NC=2C(N)=NC3=CC=CC=C3C=2N1CC1(O)CCOCC1 GDPKTEKIQSSWSV-UHFFFAOYSA-N 0.000 description 1
- FBFCNKMYYFQOEP-UHFFFAOYSA-N 4-[[4-amino-2-(2-methoxyethyl)imidazo[4,5-c][1,5]naphthyridin-1-yl]methyl]oxan-4-ol Chemical compound COCCC1=NC2=C(N)N=C3C=CC=NC3=C2N1CC1(O)CCOCC1 FBFCNKMYYFQOEP-UHFFFAOYSA-N 0.000 description 1
- BJBRZVHHGWSJIN-UHFFFAOYSA-N 4-[[4-amino-2-(3-hydroxypropyl)imidazo[4,5-c][1,5]naphthyridin-1-yl]methyl]oxan-4-ol Chemical compound OCCCC1=NC=2C(N)=NC3=CC=CN=C3C=2N1CC1(O)CCOCC1 BJBRZVHHGWSJIN-UHFFFAOYSA-N 0.000 description 1
- QSCFNEWNIDXPNP-UHFFFAOYSA-N 4-[[4-amino-2-(chloromethyl)imidazo[4,5-c]quinolin-1-yl]methyl]oxan-4-ol;hydrochloride Chemical compound Cl.ClCC1=NC=2C(N)=NC3=CC=CC=C3C=2N1CC1(O)CCOCC1 QSCFNEWNIDXPNP-UHFFFAOYSA-N 0.000 description 1
- QKVWBPILRJUACW-UHFFFAOYSA-N 4-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]oxan-4-ol Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCOCC1 QKVWBPILRJUACW-UHFFFAOYSA-N 0.000 description 1
- ZKPWKBNDFAGPEO-UHFFFAOYSA-N 4-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]piperidin-4-ol Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCNCC1 ZKPWKBNDFAGPEO-UHFFFAOYSA-N 0.000 description 1
- HQUNYGFYFGYNHV-UHFFFAOYSA-N 4-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]piperidin-4-ol;dihydrochloride Chemical compound Cl.Cl.CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCNCC1 HQUNYGFYFGYNHV-UHFFFAOYSA-N 0.000 description 1
- DHIPEYBIPDXUEH-UHFFFAOYSA-N 4-[[4-amino-2-(hydroxymethyl)imidazo[4,5-c][1,5]naphthyridin-1-yl]methyl]oxan-4-ol Chemical compound OCC1=NC=2C(N)=NC3=CC=CN=C3C=2N1CC1(O)CCOCC1 DHIPEYBIPDXUEH-UHFFFAOYSA-N 0.000 description 1
- KSTMDRNZEJKAII-UHFFFAOYSA-N 4-[[4-amino-2-(hydroxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]oxan-4-ol Chemical compound OCC1=NC=2C(N)=NC3=CC=CC=C3C=2N1CC1(O)CCOCC1 KSTMDRNZEJKAII-UHFFFAOYSA-N 0.000 description 1
- KRKXGCJUNKZXOY-UHFFFAOYSA-N 4-acetamidobenzoyl chloride Chemical compound CC(=O)NC1=CC=C(C(Cl)=O)C=C1 KRKXGCJUNKZXOY-UHFFFAOYSA-N 0.000 description 1
- QZQHTOOINKDNDA-UHFFFAOYSA-N 4-n-[3-[1-[tert-butyl(dimethyl)silyl]oxycyclohexyl]propyl]quinoline-3,4-diamine Chemical compound NC=1C=NC2=CC=CC=C2C=1NCCCC1(O[Si](C)(C)C(C)(C)C)CCCCC1 QZQHTOOINKDNDA-UHFFFAOYSA-N 0.000 description 1
- CXEFZVVLTJQWBF-UHFFFAOYSA-N 4-phenylmethoxybutanoic acid Chemical compound OC(=O)CCCOCC1=CC=CC=C1 CXEFZVVLTJQWBF-UHFFFAOYSA-N 0.000 description 1
- YHQPYMQQMBVULM-UHFFFAOYSA-N 6,7,8,9-tetrahydro-3h-imidazo[4,5-c]quinolin-4-amine Chemical compound C1CCCC2=C1N=C(N)C1=C2NC=N1 YHQPYMQQMBVULM-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HBNXMWLOQRUOOU-UHFFFAOYSA-N 8-[[(3-aminoquinolin-4-yl)amino]methyl]-1,4-dioxaspiro[4.5]decan-8-ol Chemical compound NC1=CN=C2C=CC=CC2=C1NCC(CC1)(O)CCC21OCCO2 HBNXMWLOQRUOOU-UHFFFAOYSA-N 0.000 description 1
- MVKQBRSVIRTRHJ-UHFFFAOYSA-N 8-[[(3-nitroquinolin-4-yl)amino]methyl]-1,4-dioxaspiro[4.5]decan-8-ol Chemical compound C1CC(O)(CNC=2C3=CC=CC=C3N=CC=2[N+]([O-])=O)CCC21OCCO2 MVKQBRSVIRTRHJ-UHFFFAOYSA-N 0.000 description 1
- ZWCNNQWURKJYGR-UHFFFAOYSA-N 8-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]-1,4-dioxaspiro[4.5]decan-8-ol Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC(CC1)(O)CCC21OCCO2 ZWCNNQWURKJYGR-UHFFFAOYSA-N 0.000 description 1
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo(3.3.1)nonane Chemical compound C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- ZHLJRNXPGVFACY-UHFFFAOYSA-N CCN(CC1)CCC1(CNC(C1=CC=CC=C1N=C1)=C1[N+]([O-])=O)O Chemical compound CCN(CC1)CCC1(CNC(C1=CC=CC=C1N=C1)=C1[N+]([O-])=O)O ZHLJRNXPGVFACY-UHFFFAOYSA-N 0.000 description 1
- 101100135744 Caenorhabditis elegans pch-2 gene Proteins 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 241000588881 Chromobacterium Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 208000006081 Cryptococcal meningitis Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 208000004729 Feline Leukemia Diseases 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241000721701 Lynx Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 206010027209 Meningitis cryptococcal Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000862969 Stella Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- RZJLPCFJLHBIGX-UHFFFAOYSA-N [1-(3-azidopropyl)cyclohexyl]oxy-tert-butyl-dimethylsilane Chemical compound [N-]=[N+]=NCCCC1(O[Si](C)(C)C(C)(C)C)CCCCC1 RZJLPCFJLHBIGX-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- SFLPSECZOSUZMW-UHFFFAOYSA-N [4-amino-1-[(1-hydroxycyclohexyl)methyl]imidazo[4,5-c]quinolin-2-yl]methyl acetate Chemical compound CC(=O)OCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(O)CCCCC1 SFLPSECZOSUZMW-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical group 0.000 description 1
- 125000005206 alkoxycarbonyloxymethyl group Chemical group 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 229940037642 autologous vaccine Drugs 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229930188620 butyrolactone Natural products 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- ZDQWVKDDJDIVAL-UHFFFAOYSA-N catecholborane Chemical compound C1=CC=C2O[B]OC2=C1 ZDQWVKDDJDIVAL-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 1
- KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 description 1
- UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
- BGWMHFKCAUBYJJ-UHFFFAOYSA-N ethyl 2-chloroethanimidate;hydrochloride Chemical compound Cl.CCOC(=N)CCl BGWMHFKCAUBYJJ-UHFFFAOYSA-N 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- CXVQSUBJMYZELD-UHFFFAOYSA-N ethyl 4-aminobutanoate;hydrochloride Chemical compound [Cl-].CCOC(=O)CCC[NH3+] CXVQSUBJMYZELD-UHFFFAOYSA-N 0.000 description 1
- YDUZWOVEDHQJGA-UHFFFAOYSA-N ethyl 4-hydroxy-4-[[(3-nitroquinolin-4-yl)amino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1(O)CNC1=C([N+]([O-])=O)C=NC2=CC=CC=C12 YDUZWOVEDHQJGA-UHFFFAOYSA-N 0.000 description 1
- LUBGFMZTGFXIIN-UHFFFAOYSA-N ethyl 4-oxopiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(=O)CC1 LUBGFMZTGFXIIN-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000002638 heterogeneous catalyst Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 238000006197 hydroboration reaction Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- NSHFLKZNBPJNPA-UHFFFAOYSA-N imidazo[4,5-c]quinolin-2-one Chemical class C1=CC=C2C3=NC(=O)N=C3C=NC2=C1 NSHFLKZNBPJNPA-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 1
- WBQFFOYISYSHLE-UHFFFAOYSA-N isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)[N]C(=O)C2=C1 WBQFFOYISYSHLE-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960005037 meningococcal vaccines Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- WZQCGYLBGVQKJP-UHFFFAOYSA-N n-[1-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclohexyl]acetamide Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(NC(C)=O)CCCCC1 WZQCGYLBGVQKJP-UHFFFAOYSA-N 0.000 description 1
- SHSUURUWMBZNNN-UHFFFAOYSA-N n-[1-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclopropyl]methanesulfonamide Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(NS(C)(=O)=O)CC1 SHSUURUWMBZNNN-UHFFFAOYSA-N 0.000 description 1
- BILKAIRIDCGKBO-UHFFFAOYSA-N n-[3-[1-[tert-butyl(dimethyl)silyl]oxycyclohexyl]propyl]-3-nitroquinolin-4-amine Chemical compound [O-][N+](=O)C=1C=NC2=CC=CC=C2C=1NCCCC1(O[Si](C)(C)C(C)(C)C)CCCCC1 BILKAIRIDCGKBO-UHFFFAOYSA-N 0.000 description 1
- YSBUANSGDLZTKV-UHFFFAOYSA-N n-phenylcarbamoyl chloride Chemical compound ClC(=O)NC1=CC=CC=C1 YSBUANSGDLZTKV-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 150000005054 naphthyridines Chemical class 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229960001973 pneumococcal vaccines Drugs 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- KPBSJEBFALFJTO-UHFFFAOYSA-N propane-1-sulfonyl chloride Chemical compound CCCS(Cl)(=O)=O KPBSJEBFALFJTO-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-YZRHJBSPSA-N pyridin-4-amine Chemical compound NC1=CC=N[14CH]=C1 NUKYPUAOHBNCPY-YZRHJBSPSA-N 0.000 description 1
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
- 229940070891 pyridium Drugs 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
- 102200077464 rs398122966 Human genes 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- BZPIPIMCAOJXDS-UHFFFAOYSA-N tert-butyl 4-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]-4-(2-methylsulfonylethoxy)piperidine-1-carboxylate Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC1(OCCS(C)(=O)=O)CCN(C(=O)OC(C)(C)C)CC1 BZPIPIMCAOJXDS-UHFFFAOYSA-N 0.000 description 1
- HZCZUMIXVDWWPY-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-[[(3-nitroquinolin-4-yl)amino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(O)CNC1=C([N+]([O-])=O)C=NC2=CC=CC=C12 HZCZUMIXVDWWPY-UHFFFAOYSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- VLEMHYPWKFLCDM-UHFFFAOYSA-N tert-butyl n-[1-[[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]cyclohexyl]carbamate Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CC1(NC(=O)OC(C)(C)C)CCCCC1 VLEMHYPWKFLCDM-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- ALZHIRDVXYZAFR-UHFFFAOYSA-N tert-butyl-[1-[3-[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]propyl]cyclohexyl]oxy-dimethylsilane Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CCCC1(O[Si](C)(C)C(C)(C)C)CCCCC1 ALZHIRDVXYZAFR-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 208000014754 thrombocytosis disease Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229960002109 tuberculosis vaccine Drugs 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58127404P | 2004-06-18 | 2004-06-18 | |
| US60/581,274 | 2004-06-18 | ||
| PCT/US2005/021445 WO2006028545A2 (en) | 2004-06-18 | 2005-06-17 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2005283085A1 AU2005283085A1 (en) | 2006-03-16 |
| AU2005283085B2 true AU2005283085B2 (en) | 2012-06-21 |
Family
ID=36036778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005283085A Ceased AU2005283085B2 (en) | 2004-06-18 | 2005-06-17 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7884207B2 (enExample) |
| EP (1) | EP1765348B1 (enExample) |
| JP (1) | JP5128940B2 (enExample) |
| AU (1) | AU2005283085B2 (enExample) |
| CA (1) | CA2571360C (enExample) |
| WO (1) | WO2006028545A2 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1513524A4 (en) | 2002-06-07 | 2008-09-03 | 3M Innovative Properties Co | WITH ETHER SUBSTITUTED IMIDAZOPYRIDINE |
| US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
| AR045529A1 (es) * | 2003-08-27 | 2005-11-02 | 3M Innovative Properties Co | Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi |
| AU2004270201A1 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for CD5+ B cell lymphoma |
| US8871782B2 (en) | 2003-10-03 | 2014-10-28 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
| NZ546274A (en) | 2003-10-03 | 2009-12-24 | 3M Innovative Properties Co | Pyrazolopyridines and analags thereof |
| US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| RU2409576C2 (ru) | 2003-11-25 | 2011-01-20 | 3М Инновейтив Пропертиз Компани | Системы, содержащие имидазольное кольцо с заместителями, и способы их получения |
| US8541438B2 (en) | 2004-06-18 | 2013-09-24 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
| ES2384390T3 (es) | 2004-09-02 | 2012-07-04 | 3M Innovative Properties Company | Sistemas cíclicos 1-alcoxi-1H-imidazo y métodos asociados |
| US8034938B2 (en) | 2004-12-30 | 2011-10-11 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
| EP1831226B1 (en) | 2004-12-30 | 2012-08-08 | 3M Innovative Properties Company | Chiral tetracyclic compounds inducing interferon biosynthesis |
| US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
| JP2008530252A (ja) | 2005-02-09 | 2008-08-07 | コーリー ファーマシューティカル グループ，インコーポレイテッド | オキシムおよびヒドロキシルアミンで置換されたチアゾロ［４，５−ｃ］環化合物ならびに方法 |
| AU2006212765B2 (en) | 2005-02-09 | 2012-02-02 | 3M Innovative Properties Company | Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines |
| JP2008530113A (ja) | 2005-02-11 | 2008-08-07 | コーリー ファーマシューティカル グループ，インコーポレイテッド | オキシムおよびヒドロキシラミン置換イミダゾ［４，５−ｃ］環化合物および方法 |
| CA2597446A1 (en) * | 2005-02-11 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Substituted imidazoquinolines and imidazonaphthyridines |
| JP2008538203A (ja) * | 2005-02-23 | 2008-10-16 | コーリー ファーマシューティカル グループ，インコーポレイテッド | インターフェロンの生合成を優先的に誘導する方法 |
| EP1851224A2 (en) * | 2005-02-23 | 2007-11-07 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinolines |
| JP2008531567A (ja) * | 2005-02-23 | 2008-08-14 | コーリー ファーマシューティカル グループ，インコーポレイテッド | ヒドロキシアルキル置換イミダゾキノリン化合物および方法 |
| CA2598639A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazonaphthyridines |
| EP1869043A2 (en) | 2005-04-01 | 2007-12-26 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
| WO2006107851A1 (en) * | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
| JP2009507856A (ja) * | 2005-09-09 | 2009-02-26 | コーリー ファーマシューティカル グループ，インコーポレイテッド | Ｎ−｛２−［４−アミノ−２−（エトキシメチル）−１Ｈ−イミダゾ［４，５−ｃ］キノリン−１−イル］−１，１−ジメチルエチル｝メタンスルホンアミドのアミドおよびカルバマート誘導体ならびに方法 |
| ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
| AU2006311871B2 (en) * | 2005-11-04 | 2011-03-03 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods |
| EP3085373A1 (en) | 2006-02-22 | 2016-10-26 | 3M Innovative Properties Company | Immune response modifier conjugates |
| US8329721B2 (en) * | 2006-03-15 | 2012-12-11 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods |
| FR2902100A1 (fr) * | 2006-06-13 | 2007-12-14 | Sanofi Aventis Sa | Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique |
| WO2008008432A2 (en) | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
| WO2008030511A2 (en) * | 2006-09-06 | 2008-03-13 | Coley Pharmaceuticial Group, Inc. | Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes |
| TW200827340A (en) * | 2006-11-10 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
| WO2009125809A1 (ja) * | 2008-04-11 | 2009-10-15 | 第一三共株式会社 | ピペリジン誘導体 |
| WO2009125808A1 (ja) * | 2008-04-11 | 2009-10-15 | 第一三共株式会社 | アミノシクロヘキシル誘導体 |
| US8232409B2 (en) | 2008-10-15 | 2012-07-31 | Janssen Pharmaceutica N.V. | Heterocyclic benzimidazoles as TRPM8 modulators |
| MX2012008049A (es) * | 2010-01-12 | 2012-08-01 | Hoffmann La Roche | Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,. |
| EP2397482A1 (en) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
| JP2013534248A (ja) | 2010-08-17 | 2013-09-02 | スリーエム イノベイティブ プロパティズ カンパニー | 脂質付加された免疫反応調節化合物の組成物、製剤及び方法 |
| EP3153180A1 (en) | 2011-06-03 | 2017-04-12 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
| EP2717919B1 (en) | 2011-06-03 | 2016-08-03 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| SMT202000597T1 (it) | 2013-01-07 | 2021-01-05 | Univ Pennsylvania | Composizioni e metodi per la cura del linfoma cutaneo cellule t |
| WO2014139080A1 (en) * | 2013-03-12 | 2014-09-18 | Boehringer Ingelheim International Trading (Shanghai) Co., Ltd. | Novel process for the manufacture of 3-oxo-tetrahydrofuran |
| AU2014296255B2 (en) | 2013-07-31 | 2017-08-03 | Novartis Ag | 1,4-disubstituted pyridazine derivatives and their use for treating SMN-deficiency-related conditions |
| ES2809535T3 (es) | 2013-12-09 | 2021-03-04 | UCB Biopharma SRL | Derivados de imidazopiridina como moduladores de la actividad de TNF |
| CN108026092B (zh) | 2015-08-31 | 2021-01-26 | 3M创新有限公司 | 胍取代的咪唑并[4,5-c]环化合物 |
| EP3344623B1 (en) | 2015-08-31 | 2021-02-17 | 3M Innovative Properties Company | Imidazo[4,5-c]ring compounds containing substituted guanidine groups |
| JP2018531318A (ja) * | 2015-09-29 | 2018-10-25 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | ポリマーコンジュゲートワクチン |
| US10526309B2 (en) | 2015-10-02 | 2020-01-07 | The University Of North Carolina At Chapel Hill | Pan-TAM inhibitors and Mer/Axl dual inhibitors |
| EP3484518B1 (en) | 2016-07-07 | 2024-08-14 | The Board of Trustees of the Leland Stanford Junior University | Antibody adjuvant conjugates |
| GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| EP3589631B1 (en) | 2017-03-01 | 2021-07-21 | 3M Innovative Properties Company | Imidazo[4,5-c]ring compounds containing guanidine substituted benzamide groups |
| WO2019040491A1 (en) | 2017-08-22 | 2019-02-28 | Dynavax Technologies Corporation | MODIFIED ALKYL CHAIN IMIDAZOQUINOLINE TLR7 / 8 AGONIST COMPOUNDS AND USES THEREOF |
| WO2019048036A1 (en) * | 2017-09-06 | 2019-03-14 | Biontech Ag | SUBSTITUTED IMIDAZOQUINOLINES |
| EP3710059A1 (en) | 2017-11-14 | 2020-09-23 | Dynavax Technologies Corporation | Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof |
| CA3086439A1 (en) | 2017-12-20 | 2019-06-27 | 3M Innovative Properties Company | Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier |
| BR112020016859A2 (pt) | 2018-02-28 | 2020-12-29 | Pfizer Inc. | Variantes de il-15 e usos da mesma |
| JP7251893B2 (ja) | 2018-02-28 | 2023-04-04 | スリーエム イノベイティブ プロパティズ カンパニー | Ｎ－１分枝基を有する置換イミダゾ［４，５－ｃ］キノリン化合物 |
| DK3797121T3 (da) | 2018-05-23 | 2024-07-08 | Pfizer | Antistoffer, der er specifikke for CD3, og anvendelser deraf |
| TWI816396B (zh) | 2018-05-23 | 2023-09-21 | 美商輝瑞大藥廠 | 特異性針對gucy2c之抗體及其用途 |
| US11884662B2 (en) | 2018-05-24 | 2024-01-30 | 3M Innovative Properties Company | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods |
| WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| EP3946606B1 (en) | 2019-03-27 | 2025-01-01 | Insilico Medicine IP Limited | Bicyclic jak inhibitors and uses thereof |
| US11458163B2 (en) | 2019-04-17 | 2022-10-04 | University Of Kansas | Platinum(IV) conjugates and methods of use |
| KR20220068243A (ko) * | 2019-09-23 | 2022-05-25 | 난징 젱시앙 파마슈티칼스 컴퍼니 리미티드 | 포스포디에스테라제 억제제 및 용도 |
| PE20230160A1 (es) | 2019-12-17 | 2023-02-01 | Pfizer | Anticuerpos especificos para cd47, pd-l1 y sus usos |
| EP4182346A1 (en) | 2020-07-17 | 2023-05-24 | Pfizer Inc. | Therapeutic antibodies and their uses |
| WO2025104289A1 (en) | 2023-11-17 | 2025-05-22 | Medincell S.A. | Antineoplastic combinations |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005123079A2 (en) * | 2004-06-14 | 2005-12-29 | 3M Innovative Properties Company | Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3314941A (en) * | 1964-06-23 | 1967-04-18 | American Cyanamid Co | Novel substituted pyridodiazepins |
| GR79630B (enExample) * | 1982-08-18 | 1984-10-31 | Falkenried Fahrzeug Gmbh | |
| IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| ZA848968B (en) * | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
| US5238944A (en) * | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| US5756747A (en) * | 1989-02-27 | 1998-05-26 | Riker Laboratories, Inc. | 1H-imidazo 4,5-c!quinolin-4-amines |
| US5037986A (en) * | 1989-03-23 | 1991-08-06 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines |
| US4929624A (en) * | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| NZ232740A (en) | 1989-04-20 | 1992-06-25 | Riker Laboratories Inc | Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster |
| US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
| DK0553202T3 (da) * | 1990-10-05 | 1995-07-03 | Minnesota Mining & Mfg | Fremgangsmåde til fremstilling af imidazo(4,5-c)quinolin-4-aminer |
| ES2186034T3 (es) * | 1991-03-01 | 2003-05-01 | Minnesota Mining & Mfg | Intermedios para la preparacion de 1h-imidazo(4,5-c)quinolin-4-aminas 1-sustituidas, 2-sustituidas. |
| US5175296A (en) * | 1991-03-01 | 1992-12-29 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]quinolin-4-amines and processes for their preparation |
| US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5268376A (en) * | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5266575A (en) * | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| IL105325A (en) * | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| US5395937A (en) * | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| CZ288182B6 (en) * | 1993-07-15 | 2001-05-16 | Minnesota Mining & Mfg | Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon |
| US5482936A (en) * | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| JPH09176116A (ja) * | 1995-12-27 | 1997-07-08 | Toray Ind Inc | 複素環誘導体およびその医薬用途 |
| JPH09208584A (ja) | 1996-01-29 | 1997-08-12 | Terumo Corp | アミド誘導体、およびそれを含有する医薬製剤、および合成中間体 |
| US5693811A (en) * | 1996-06-21 | 1997-12-02 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahdroimidazoquinolinamines |
| US5741908A (en) * | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
| CA2268957C (en) * | 1996-10-25 | 2008-04-29 | Minnesota Mining And Manufacturing Company | Immune response modifier compounds for treatment of th2 mediated and related diseases |
| US5939090A (en) * | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
| WO1998030562A1 (en) * | 1997-01-09 | 1998-07-16 | Terumo Kabushiki Kaisha | Novel amide derivatives and intermediates for the synthesis thereof |
| JPH1180156A (ja) | 1997-09-04 | 1999-03-26 | Hokuriku Seiyaku Co Ltd | １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体 |
| UA67760C2 (uk) * | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
| JPH11222432A (ja) | 1998-02-03 | 1999-08-17 | Terumo Corp | インターフェロンを誘起するアミド誘導体を含有する外用剤 |
| US6110929A (en) * | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| JP2000119271A (ja) * | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| EP1140091B1 (en) * | 1999-01-08 | 2005-09-21 | 3M Innovative Properties Company | Formulations comprising imiquimod or other immune response modifiers for treating cervical dysplasia |
| US20020058674A1 (en) * | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
| US6558951B1 (en) * | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| JP2000247884A (ja) | 1999-03-01 | 2000-09-12 | Sumitomo Pharmaceut Co Ltd | アラキドン酸誘発皮膚疾患治療剤 |
| US6331539B1 (en) * | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US6451810B1 (en) * | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6756382B2 (en) * | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6573273B1 (en) * | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6541485B1 (en) * | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6376669B1 (en) * | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
| US6894060B2 (en) * | 2000-03-30 | 2005-05-17 | 3M Innovative Properties Company | Method for the treatment of dermal lesions caused by envenomation |
| US20020055517A1 (en) * | 2000-09-15 | 2002-05-09 | 3M Innovative Properties Company | Methods for delaying recurrence of herpes virus symptoms |
| JP2002145777A (ja) | 2000-11-06 | 2002-05-22 | Sumitomo Pharmaceut Co Ltd | アラキドン酸誘発皮膚疾患治療剤 |
| US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
| US6545016B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
| US6664264B2 (en) * | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6677348B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
| US6664265B2 (en) * | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| WO2002046749A2 (en) * | 2000-12-08 | 2002-06-13 | 3M Innovative Properties Company | Screening method for identifying compounds that selectively induce interferon alpha |
| US20020107262A1 (en) * | 2000-12-08 | 2002-08-08 | 3M Innovative Properties Company | Substituted imidazopyridines |
| US6660735B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
| US6660747B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US6667312B2 (en) * | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| UA74852C2 (en) * | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
| US6525064B1 (en) * | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
| US6664260B2 (en) * | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
| US6545017B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
| MXPA04001972A (es) * | 2001-08-30 | 2005-02-17 | 3M Innovative Properties Co | Metodos para hacer madurar celulas dendricas plasmacitoide utilizando moleculas modificadoras de respuesta enmune. |
| ATE511840T1 (de) * | 2001-10-09 | 2011-06-15 | Amgen Inc | Imidazolderivate als entzündungshemmende mittel |
| AU2002360278A1 (en) * | 2001-10-12 | 2003-11-11 | Coley Pharmaceutical Gmbh | Methods and products for enhancing immune responses using imidazoquinoline compounds |
| AU2002343728A1 (en) * | 2001-11-16 | 2003-06-10 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor pathways |
| US20030199538A1 (en) * | 2001-11-29 | 2003-10-23 | 3M Innovative Properties Company | Pharmaceutical formulation comprising an immune response modifier |
| US6677349B1 (en) * | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| HUE025145T2 (en) * | 2002-02-22 | 2016-01-28 | Meda Ab | A method for reducing and treating immunosuppression induced by ultraviolet B radiation |
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| JP2005531599A (ja) * | 2002-05-29 | 2005-10-20 | スリーエム イノベイティブ プロパティズ カンパニー | イミダゾ［４，５−ｃ］ピリジン−４−アミンのための方法 |
| EP1513524A4 (en) * | 2002-06-07 | 2008-09-03 | 3M Innovative Properties Co | WITH ETHER SUBSTITUTED IMIDAZOPYRIDINE |
| KR20050028047A (ko) * | 2002-07-23 | 2005-03-21 | 비오갈 기오기스제르갸르 알티. | 1ｈ-이미다조[4,5-ｃ]퀴놀린-4-프탈이미드 중간체를 통한1ｈ-이미다조[4,5-ｃ]퀴놀린-4-아민의 제조 |
| WO2004011462A1 (en) * | 2002-07-26 | 2004-02-05 | Biogal Gyogyszergyar Rt. | Preparation of 1h-imidazo [4,5-c] quinolin-4-amines via novel 1h-imidazo [4,5-c] quinolin-4-cyano and 1h-imidazo [4,5-c] quinolin-4-carboxamide intermediates |
| DK1545597T3 (da) * | 2002-08-15 | 2011-01-31 | 3M Innovative Properties Co | Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons |
| EP1542688A4 (en) * | 2002-09-26 | 2010-06-02 | 3M Innovative Properties Co | 1H-imidazo dimers |
| AU2003287324A1 (en) * | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
| AU2003287316A1 (en) * | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
| WO2004058759A1 (en) * | 2002-12-20 | 2004-07-15 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
| AU2003300184B8 (en) * | 2002-12-30 | 2009-12-03 | 3M Innovative Properties Company | Immunostimulatory combinations |
| WO2004071459A2 (en) * | 2003-02-13 | 2004-08-26 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor 8 |
| EP1599726A4 (en) * | 2003-02-27 | 2009-07-22 | 3M Innovative Properties Co | SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY |
| AU2004218349A1 (en) * | 2003-03-04 | 2004-09-16 | 3M Innovative Properties Company | Prophylactic treatment of UV-induced epidermal neoplasia |
| TW200505458A (en) * | 2003-03-07 | 2005-02-16 | 3M Innovative Properties Co | 1-amino 1h-imidazoquinolines |
| US8426457B2 (en) * | 2003-03-13 | 2013-04-23 | Medicis Pharmaceutical Corporation | Methods of improving skin quality |
| US7699057B2 (en) * | 2003-03-13 | 2010-04-20 | 3M Innovative Properties Company | Methods for treating skin lesions |
| AU2004220465A1 (en) * | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Method of tattoo removal |
| WO2004087049A2 (en) * | 2003-03-25 | 2004-10-14 | 3M Innovative Properties Company | Selective activation of cellular activities mediated through a common toll-like receptor |
| US20040192585A1 (en) * | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
| JP2006522823A (ja) * | 2003-04-10 | 2006-10-05 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫反応調節物質化合物の送達 |
| EP1617845A4 (en) * | 2003-04-28 | 2006-09-20 | 3M Innovative Properties Co | COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS |
| US8673932B2 (en) | 2003-08-12 | 2014-03-18 | 3M Innovative Properties Company | Oxime substituted imidazo-containing compounds |
| PL1653959T3 (pl) | 2003-08-14 | 2015-10-30 | 3M Innovative Properties Co | Modyfikatory odpowiedzi immunologicznej modyfikowane lipidami |
| BRPI0414045A (pt) * | 2003-09-05 | 2006-10-24 | Anadys Pharmaceuticals Inc | administração de ligantes de tlr7 e pró-medicamentos dos mesmos para tratamento de infecção por vìrus de hepatite c |
| WO2005033049A2 (en) * | 2003-10-01 | 2005-04-14 | Taro Pharmaceuticals U.S.A., Inc. | METHOD OF PREPARING 4-AMINO-1H-IMIDAZO(4,5-c)QUINOLINES AND ACID ADDITION SALTS THEREOF |
| ITMI20032121A1 (it) * | 2003-11-04 | 2005-05-05 | Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm | Procedimento per la preparazione di imiquimod e suoi intermedi |
| US7897609B2 (en) * | 2004-06-18 | 2011-03-01 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
-
2005
- 2005-06-17 EP EP05814989.9A patent/EP1765348B1/en not_active Expired - Lifetime
- 2005-06-17 CA CA2571360A patent/CA2571360C/en not_active Expired - Fee Related
- 2005-06-17 WO PCT/US2005/021445 patent/WO2006028545A2/en not_active Ceased
- 2005-06-17 US US11/570,707 patent/US7884207B2/en not_active Expired - Fee Related
- 2005-06-17 AU AU2005283085A patent/AU2005283085B2/en not_active Ceased
- 2005-06-17 JP JP2007516773A patent/JP5128940B2/ja not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005123079A2 (en) * | 2004-06-14 | 2005-12-29 | 3M Innovative Properties Company | Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
Also Published As
| Publication number | Publication date |
|---|---|
| US20070287724A1 (en) | 2007-12-13 |
| CA2571360A1 (en) | 2006-03-16 |
| AU2005283085A1 (en) | 2006-03-16 |
| US7884207B2 (en) | 2011-02-08 |
| EP1765348B1 (en) | 2016-08-03 |
| WO2006028545A3 (en) | 2007-08-23 |
| JP5128940B2 (ja) | 2013-01-23 |
| EP1765348A2 (en) | 2007-03-28 |
| CA2571360C (en) | 2014-11-25 |
| JP2008503484A (ja) | 2008-02-07 |
| WO2006028545A2 (en) | 2006-03-16 |
| EP1765348A4 (en) | 2010-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005283085B2 (en) | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | |
| AU2006311871B2 (en) | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods | |
| US7939526B2 (en) | Sulfone substituted imidazo ring ethers | |
| AU2005322898B2 (en) | Chiral fused (1,2)imidazo(4,5-c) ring compounds | |
| US9938275B2 (en) | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | |
| AU2005282523A1 (en) | 2-amino 1H imidazo ring systems and methods | |
| AU2006216686A1 (en) | Method of preferentially inducing the biosynthesis of interferon | |
| AU2006216799A1 (en) | Hydroxyalkyl substituted imidazonaphthyridines | |
| AU2004278014A1 (en) | Alkoxy substituted imidazoquinolines | |
| AU2004312508A1 (en) | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides | |
| WO2006009832A1 (en) | Substituted imidazo ring systems and methods | |
| WO2005123079A2 (en) | Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines | |
| WO2006026760A2 (en) | 1-amino imidazo-containing compounds and methods | |
| AU2006232377A1 (en) | Pyrazolopyridine-1,4-diamines and analogs thereof | |
| AU2006213746A1 (en) | Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods | |
| AU2006287157A1 (en) | Hydroxy substituted 1H-imidazopyridines and methods | |
| AU2004291101A1 (en) | Oxime substituted imidazo ring compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |